Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep 29;15(10):2148.
doi: 10.3390/ijerph15102148.

Depression Negatively Impacts Survival of Patients with Metastatic Prostate Cancer

Po-Hung Lin  1   2 , Jui-Ming Liu  3   4   5 , Ren-Jun Hsu  6   7   8 , Heng-Chang Chuang  9 , Su-Wei Chang  10   11 , See-Tong Pang  12 , Ying-Hsu Chang  13 , Cheng-Keng Chuang  14 , Shun-Ku Lin  15   16
Affiliations

Depression Negatively Impacts Survival of Patients with Metastatic Prostate Cancer

Po-Hung Lin et al. Int J Environ Res Public Health. .

Abstract

The prevalence of depression in patients with cancer is high, especially for patients with advanced cancer. In this study, we evaluated the prevalence of depression in prostate cancer patients in Taiwan and the association between depression and mortality in prostate cancer. This study included 1101 newly diagnosed patients with prostate cancer. We tracked the medical information of these patients from diagnosis until the end of 2012. Patients were divided into two groups according to presence or absence of depression diagnosis, and were further divided into three stages by initial treatments: localized or locally advanced, metastatic, and castration-resistant prostate cancer. Of 1101 participants, 267 (24.3%) had depression. By the end of the follow-up period (M = 8.30 ± 3.12 years), 77 (28.8%) patients in the depression group and 194 (23.3%) in the non-depressed group died. Depression was associated with higher mortality risk, (aHR 1.37; 95% CI [ 1.04⁻1.80]; p value 0.01). Patients in the metastatic prostate cancer group with depression had a significantly higher mortality risk compared to the non-depressed group, (aHR, 1.49; 95% CI [1.05⁻2.11]; p value 0.02). The impact of depression on mortality risk was not significant in either the localized or locally advanced or the castration-resistant prostate cancer groups. Our study showed that depression is related to an increased mortality risk for patients with prostate cancer, especially for metastatic prostate cancer. These results indicate that urologists should pay attention to the mood and psychiatric disorders of patients with prostate cancer.

Keywords: National Health Insurance Research Dataset; cancer survival; depression; metastatic prostate cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Of 1101 participants, 267 (24.3%) had depression. By the end of the follow-up period (M = 8.30 ± 3.12 years), 77 (28.8%) patients in the depression group and 194 (23.3%) in the non-depressed group died.
Figure 2
Figure 2
The Kaplan-Meier survival curve for patients with prostate cancer according to depression. The survival rate in patients with depression was significantly lower compared to those without depression, and the p value of the log-rank test was 0.0247.
Figure 3
Figure 3
The Kaplan-Meier survival curve for patients with metastatic prostate cancer according to depression. Patients with depression in the metastatic prostate cancer group had significantly lower survival rates compared with patients without depression, and the p value of log-rank test was 0.0004.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Canoui-Poitrine F., Reinald N., Laurent M., Guery E., Caillet P., David J.P., Tournigand C., Lagrange J.L., Bastuji-Garin S., Lemogne C., et al. Geriatric assessment findings independently associated with clinical depression in 1092 older patients with cancer, the ELCAPA cohort study. Psychooncology. 2016;25:104–111. doi: 10.1002/pon.3886. - DOI - PubMed
    1. Meyer F., Fletcher K., Prigerson H.G., Braun I.M., Maciejewski P.K. Advanced cancer as a risk for major depressive episodes. Psychooncology. 2015;24:1080–1087. doi: 10.1002/pon.3722. - DOI - PMC - PubMed
    1. Raison C.L., Miller A.H. Depression in cancer, new developments regarding diagnosis and treatment. Biol. Psychiatry. 2003;54:283–294. doi: 10.1016/S0006-3223(03)00413-X. - DOI - PubMed
    1. Giese-Davis J., Collie K., Rancourt K.M., Neri E., Kraemer H.C., Spiegel D. Decrease in depression symptoms is associated with longer survival in patients with metastatic breast cancer: A secondary analysis. J. Clin. Oncol. 2011;29:413–420. doi: 10.1200/JCO.2010.28.4455. - DOI - PMC - PubMed
    1. Steel J.L., Geller D.A., Gamblin T.C., Olek M.C., Carr B.I. Depression, immunity, and survival in patients with hepatobiliary carcinoma. J. Clin. Oncol. 2007;25:2397–2405. doi: 10.1200/JCO.2006.06.4592. - DOI - PubMed

Publication types